Phase II trial of toripalimab plus chemotherapy as neoadjuvant treatment in resectable stage III non-small cell lung cancer (NeoTPD01 Study).

医学 培美曲塞 卡铂 肺癌 临床终点 内科学 肿瘤科 化疗 腺癌 外科 癌症 人口 阶段(地层学) 新辅助治疗 临床试验 乳腺癌 顺铂 古生物学 环境卫生 生物
作者
Ze-Rui Zhao,Si Chen,Han Qi,Chaopin Yang,Yaobin Lin,Jietian Jin,Shanshan Lian,Yizhi Wang,Hui Yu,Long Hao
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): 8541-8541 被引量:13
标识
DOI:10.1200/jco.2021.39.15_suppl.8541
摘要

8541 Background: Multi-modality treatment provides modest survival benefits for locally advanced non-small-cell lung cancer (NSCLC) patients. Preoperative immunotherapy has continuously been shown to be promising in treating resectable NSCLC. The current study aimed to investigate the activity and safety of the PD-1 inhibitor, toripalimab, with chemotherapy given as neoadjuvant treatment for resectable stage III NSCLC in Asian population. Methods: Eligible patients recruited were aged 18 years or older with histologically confirmed AJCC-defined stage IIIA or T3-4N2 IIIB NSCLC who deemed surgically resectable. Patients received 3 cycles of neoadjuvant treatment with intravenous toripalimab (240 mg), carboplatin (area under curve 5), and pemetrexed (500 mg/m2 for adenocarcinoma) or nab-paclitaxel (260 mg/m2 for others) on day 1 of each 21-day cycle. Surgical resection was performed 4-5 weeks following the first day of the last cycle of treatment. The primary endpoint was major pathological response (MPR; ≤10% viable tumor cells). Secondary endpoints included pathological complete response (pCR), R0 resection rate, disease-free survival and safety. Paired primary tumor +/- lymph node and blood samples at baseline and surgery were obtained for exploratory study. This study is registered with ClinicalTrials.gov, NCT04304248. Results: Between August 2019 and July 2020, 33 patients (median age: 61, IQR: 56-66; female: 6, 18.2%) were enrolled and received neoadjuvant treatment. 18 (54.5%) patients had squamous cell lung cancer, and 13 (39.4%) had T3-4N2 stage IIIB disease. Two patients refused surgery and one had progressive disease after treatment. 30 (91.9%) patients underwent resection (median interval between neoadjuvant treatment and surgery: 36.5 days, IQR 30-42.5) and all except one achieved R0 resection (29/30, 96.7%). 20 patients (20/30, 66.7%) had an MPR, including 15 patients (15/30, 50.0%) had a pCR in the per-protocol population. Surgical complications included three arrhythmias, one prolonged air leak, and one chylothorax. 24 patients (80.0%) had pathological downstaging following treatment, and complete lymph node clearances (ypN0) were seen in 70.0% (21/30) of patients. The most common grade 3-4 treatment-related adverse events in the intention-to-treat population were anemia (2, [6.0%]). Severe treatment-related adverse event included one (3.0%) patient with grade 3 peripheral neuropathy (Guillain-Barré syndrome) and resulted in surgery cancellation. At the time of data cutoff (Feb 7, 2021), the median duration of follow-up was 4.13 months, and there were no treatment-related deaths. Conclusions: Toripalimab plus platinum-based doublet yields a high MPR rate, manageable treatment-related toxicity, and feasible surgical resection in resectable stage III NSCLC. Ongoing analysis of biomarker will be available at the meeting. Clinical trial information: NCT04304248.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
一米阳光发布了新的文献求助10
1秒前
香蕉觅云的应助被Besttin9799采纳,获得30
1秒前
刘白完成签到,获得积分10
1秒前
Tracy发布了新的文献求助10
1秒前
LIUDAN发布了新的文献求助10
2秒前
3秒前
dieeee完成签到,获得积分10
4秒前
TaoJ的应助被ku采纳,获得10
5秒前
平淡的凌寒完成签到,获得积分10
5秒前
温柔发卡发布了新的文献求助10
5秒前
...完成签到,获得积分10
6秒前
哈基米德发布了新的文献求助10
7秒前
朴实的哲瀚完成签到 ,获得积分20
7秒前
展望未来完成签到 ,获得积分10
9秒前
10秒前
10秒前
小白菜完成签到,获得积分10
11秒前
一个橡果完成签到,获得积分10
11秒前
13秒前
poison完成签到 ,获得积分10
13秒前
13秒前
山海不远发布了新的文献求助30
14秒前
星辰大海的应助被哈基米德采纳,获得10
16秒前
万能图书馆的应助被邱化兴采纳,获得10
16秒前
华仔的应助被Jenson采纳,获得10
17秒前
Besttin9799发布了新的文献求助30
18秒前
18秒前
科研小李发布了新的文献求助10
18秒前
深情安青的应助被smx111采纳,获得20
18秒前
18秒前
无极微光的应助被饱满南松采纳,获得20
19秒前
19秒前
Liu6868完成签到,获得积分10
20秒前
斯文败类的应助被lyy采纳,获得10
21秒前
21秒前
东都行完成签到,获得积分10
21秒前
21秒前
科研通AI6.2的应助被闯天涯采纳,获得10
22秒前
温柔发卡完成签到,获得积分10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183667
求助须知:如何正确求助?哪些是违规求助? 9572953
关于积分的说明 21828185
捐赠科研通 7780853
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558251
邀请新用户注册赠送积分活动 2480500